// App-Quantinova.ai

OP074 : Direct implantation of rapamycin-eluting stents with bioresorbable drug carrier technology utilising a drug-eluting coronary stent integrated delivery system (IDS): the DIRECT II study

Researchers

Presenter

  • Verheye S

Principal Investigators

  • Stella P

  • Carrie D

  • Khattab A

  • Serruys P

Medical Centers

  • AZ Middelheim Hospital, Antwerp, Belgium

  • Hopital Rangueil, Toulouse, France

  • Inselspital, Bern, Switzerland

Locations

  • France

  • Switzerland

  • Belgium

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

  • Blood/haematological Diseases

  • Pulmonary/Respiratory Diseases

Disease

  • Venous thrombosis

Biomarkers

  • N/A

Drug/Treatment

  • Rapacan

  • TOP-5

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved